Faculty Research

Many of the faculty at the Fuqua School of Business, and throughout Duke University, are recognized internationally as innovative thought leaders and researchers across the health care spectrum. In addition to Health Sector Management (HSM) and Fuqua, many hold appointments with the Duke schools of medicine, law, public policy, environment and engineering, and are affiliated with a variety of health-related organizations worldwide.

Mark McClellan & Gregory Daniel: Off-Label Oncology Drugs and Evidence Development

Drs. Mark McClellan and Gregory Daniel of the Duke-Margolis Center for Health Policy describe ways to increase evidence development for off-label drugs in oncology. They outline two pathways by which evidence development has been explored, through the ASCO TAPUR study …

Bill Boulding & Richard Staelin: Financial Health Impacts on Quality of Patient Care

Fuqua’s Dean Bill Boulding, Professor Richard Staelin, alumni Matthew Manary and Seth Glickman studied the impact of a hospital’s financial health on quality of care. Currently, the US government penalizes lower-performing hospitals with lower reimbursements, which in turn could lead …

Barak Richman: Health Systems and Antitrust Policies

In this article, Duke Law and Fuqua Professor Barak D. Richman and coauthors discuss the court ruling that disallowed Partners Health Care in Suffolk County, MA from adding three additional providers to their health system. The publication explores the impact …

Peter Ubel: Improving the Design of Health Insurance Exchanges

Dr. Peter Ubel, HSM Associate Faculty Director, and colleagues discuss the impact of the layout of the online health insurance exchanges on consumer choices by employing behavioral science methods and design architecture. They argue that “powerful connotative labels” and tables …

Mark McClellan & Gregory Daniel: Innovation Metrics for Pharma Development

Drs. Mark McClellan and Gregory Daniel of the Duke-Margolis Center for Health Policy outline the development of a database that provides a more comprehensive, publicly-available measure of innovation. Currently, the most common metrics for innovation are development time, R&D spending, …

Mark McClellan & Gregory Daniel: Market Challenges for Antibiotic Development

Drs. Mark McClellan and Gregory Daniel of the Duke-Margolis Center of Health Policy address the need for new antibiotic drug development. While there is a huge need for innovation and research because bacterial strains grow resistant to drugs with time, …

Aaron Chatterji: The Market for Ideas in the Medical Device Industry

Fuqua professor Aaron Chatterji and colleague Kira Fabrizio studied the effect of the market for ideas, or collaborations between inventors and health care companies to develop new products, on the speed and direction of new innovation. Innovation typically does not …

David Ridley: Drug Copayments, Advertising, and Demand

HSM Faculty Director David B. Ridley examined how differences in drug copayments influence drug demand. He used data on branded proton pump inhibitors from 77 insurance groups over the course of 25 months between 2000 and 2002. Previous studies examined …

Donald Taylor: Patient Preferences and Medicare Benefits

Professor Donald Taylor and coauthors conducted a study to test cancer patients’ preferences around benefits covered by Medicare. The results revealed the importance of quality of life care and an eased financial burden. The participant profile included those 65 and …

Ryan McDevitt: Health Care, Gender Disparities, and Market Structure

Fuqua School of Business professor Ryan McDevitt, with coauthor James Roberts, conducted an analysis of urologists in the United States in the years 2006 and 2009, discharged patients in Florida between January 2006 and June 2008, and cancer deaths between …